Please login to the form below

Not currently logged in
Email:
Password:

market share

This page shows the latest market share news and features for those working in and with pharma, biotech and healthcare.

Launch leaders' blog: what should launch leaders be measuring?

Launch leaders' blog: what should launch leaders be measuring?

What market and class share can we expect? What’s the likely uptake vs previous launches in our company or in the class? ... Tracking to the critical launch path timeline – ie speed to market for regulatory, pricing/ access, supply and commercial

Latest news

More from news
Approximately 0 fully matching, plus 561 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 79 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Webinar

    Monitoring the impact of COVID-19 on the market access landscape. Register now for Research Partnership's next live webinar in which their specialist market access team will share insights from ... their COVID-19 impact study and advise how

  • Are biobetters a market access opportunity?

    This produces time pressure for biobetters to make it to market before a biosimilar, to avoid the downward price pressure a biosimilar creates. ... Moreover, biobetters will need to enter the market before the exclusivity period of the patented reference

  • The 'winner takes all' pricing game

    Each hospital is tendering for full volume in a 'winner takes all' market. ... One of the core reasons is that almost all pharmaceutical companies use market share and sales as the most important key performance indicators of commercial and management

  • Creative problem solving, solved

    In fact, companies that actively foster creative thinking outperform their rivals in revenue growth, market share and competitive leadership, according to the report.

  • Good data is nothing without advocacy

    Additionally, the healthcare market is becoming an increasingly ‘noisy’ environment, restricted by tighter budgets and more stringent compliance codes, with drug developments often being only incremental. ... What barriers are there to increasing the

More from PMHub
Approximately 1 fully matching, plus 32 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics